Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8219924 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
When RT and sorafenib therapy were combined in patients with unresectable HCC, the initial complete or partial response rate was 55% with a 2-year IFPS of 39%. A CLIP score â¥2 was associated with an inferior outcome in overall survival. Hepatic toxicities are a major determinant of the safety; the combination should be used with caution and needs further investigation.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Shang-Wen MD, Li-Ching MD, Yu-Cheng MD, PhD, Ji-An MD, Chia-Chun MD, Jeng-Fong MD, PhD,